Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ANIXBullishCorporate Developmentsnews

High materiality7/10

ANIX Reports Encouraging Safety and Long-Term Survival Signals in FSHR CAR-T Trial

Oct 1, 2026, 8:46 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Early safety successes and multi-quarter survival signals in a difficult ovarian cancer setting can de-risk the platform, potentially lifting multiple-year valuation if data persist, despite the narrow Phase 1 scope.

AI summary

What happened, with direct paths to the underlying reporting

Anixa Biosciences reports encouraging safety signals in its FSHR-targeted CAR-T trial for recurrent ovarian cancer, with the fifth cohort dosing at 1×10^7 CAR+ cells/kg and no dose-limiting toxicities. Several patients have survived beyond one year, including one over two years, in a heavily pre-treated population, underscoring potential for CER-T and the lira-cel program if enrollment continues and data mature.

Second patient treated in ANIX's fifth FSHR CAR-T cohort.
Cohort 5 dose: 1×10^7 CAR+ cells/kg; highest to date.
No dose-limiting toxicities observed across cohorts.
Several patients surpass one year post-treatment; one beyond two years.
Durable signals in heavily pre-treated ovarian cancer may support CER-T/lira-cel progression.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.